254 results about "Cyclic hydrocarbon" patented technology

The invention relates to a compound of general formula (I):

X-L-Y  (I)

in which X and Y are pharmaceutically active moieties which may be the same or different; and L is a linker which is an optionally substituted saturated or unsaturated straight chain, branched and/or cyclic hydrocarbon radical having a backbone of at least 11 atoms, or a pharmaceutically acceptable derivative or salt thereof, methods for their preparation, pharmaceutical formulations containing them or their use in the prevention or treatment of a microbial infection.

A method for producing nano-carbon materials, having a step wherein a starting material comprising one or more kinds of compounds selected from the group consisting saturated hydrocarbons, unsaturated hydrocarbons, saturated cyclic hydrocarbons, and alcohols whose atomic ratio of the component carbon to the component oxygen is more than 2.0 and a catalyst are together treated at a temperature in a range of from 100 to 800° C. while being compressed at a pressure in a range of from 0.2 to 60 MPa, where said starting material is converted into a supercritical fluid or a subcritical fluid while said supercritical fluid or said subcritical fluid being contacted with said catalyst, or a step wherein said starting material, said catalyst and a supplementary material capable of functioning as a reaction promotion medium are together treated at a temperature in a range of from 100 to 800° C. while being compressed at a pressure in a range of from 0.2 to 60 MPa, where at least said supplementary material is converted into a supercritical fluid or a subcritical fluid and said starting material is contacted with said supercritical fluid or said subcritical fluid formed from said supplementary material while being contacted with said catalyst.

There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I):

wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O)₂— or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z¹ and Z³ independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z² represents —N(R¹)—, —O—, —S(O)—, —S(O)₂—, —CO—, —CH(R¹)— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R¹ to form an optionally substituted ring, and a represents 0, 1 or 2.

The present invention provides a lipid-rich plaque regressing agent comprising a compound represented by Formula:

in which ring A is a cyclic hydrocarbon or the like; ring B is a heterocyclic ring or the like; each of X and Y is —NR¹— (in which R¹ is a hydrocarbon or the like); D is a C_1-3 alkylene group or the like; E is —NH— or the like; G is a bond or the like; and Ar is an aryl or the like; D may be taken together with a constituent atom of the ring B to form a ring, and R⁴ may be taken together with a constituent atom of the ring B to form a ring.

The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.

The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused;

• • R¹: a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3;
  • X: single bonding arm, —CH₂—, —CO—, —(CH₂)_m—CO—, —CH(R²)—CO—, —(CH₂)_p—Y—(C(R³)(R⁴))_q—CO—, —NH—CO— or —N(R⁵)—CO—;
  • in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R¹; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2;
  • Y: —O— or —SO₂—;
  • R²: phenyl or lower alkyl;
  • R³, R⁴: each independently represents hydrogen atom or lower alkyl;
  • R⁵: lower alkyl;
  • provided that the ring portion of the group represented by R¹ is neither naphthylidine nor partially saturated group thereof, and, when X is —CH₂— or —CO—, R¹ is not naphthyl.

A homoadamantane derivative represented by the following formula (I): wherein R¹ and R² are independently a hydrogen atom or a linear, branched or cyclic hydrocarbon group having 1 to 6 carbon atoms, x is a hydroxyl group or a halogen atom, and n and m are independently an integer of 0 to 3, provided that n and m are not simultaneously 0.

A compound represented by formula (1):

Q¹-Q²-T⁰-N(R¹)-Q³-N(R²)-T¹-Q⁴  (1)

[wherein R¹ and R² are hydrogen atoms or the like; Q¹ is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q² is a single bond or the like; Q³ represents the following group:

(wherein Q⁵ is an alkylene group having 1 to 8 carbon atoms, or the like); and T⁰ and T¹ are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.

The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

An immersion exposure liquid which exhibits a high refractive index, prevents elution and dissolution of a photoresist film or its upper layer film component, and reduces defects during formation of a resist pattern when used in an immersion exposure method, and an immersion exposure method using the immersion exposure liquid. The immersion exposure liquid is used for an immersion exposure device or an immersion exposure method in which a substrate is exposed through a liquid provided between a lens of a projection optical system and the substrate, the immersion exposure liquid being liquid in an operating temperature range of the immersion exposure device and including an alicyclic hydrocarbon compound or a cyclic hydrocarbon compound containing a silicon atom in the ring structure.

An anti-smudge body having a surface that, when fingerprints adhere to the surface, allows the fingerprint patterns to spread spontaneously to thereby cause the adhering fingerprints to become less noticeable has a surface and a fine irregular structure provided to the surface, wherein the irregular structure contains at least one of a first compound having an ester linkage in a portion other than terminal ends and a second compound having a cyclic hydrocarbon group.

The invention relates to a low-temperature aqueous-phase catalyst for lignin phenol derivative hydrodeoxygenation and a preparation method thereof. The catalyst comprises a zeolite molecular sieve HBeta serving as a carrier and a load Ru, wherein the molar ratio of silicon to aluminum is 10-50, and the loading amount of Ru is 0.1 to 2%. The preparation method comprises the following steps: mixing measured aqueous solution of RuCl3 with a zeolite suspension, evaporating water and drying, and then reducing the obtained solid with hydrogen/argon mixed gas. A cyclic hydrocarbon (the conversion rate is greater than 98% and the selectivity is greater than 95%) is prepared at high selectivity under the relatively mild (100-150 DEG C and 1-4MPa) condition, so that the defects that the reaction conditions are harsh and the energy efficiency is low in the refining process of biomass pyrolysis oil can be overcome. The bifunctional catalyst provided by the invention has the advantages of simplicity and easiness in operation in the preparation process, stable physical and chemical properties, and direct application. At low temperatures, the catalyst shows excellent hydrodeoxygenation activity and extremely high selectivity of saturated hydrocarbons, has a simple and environment-friendly reaction process, and can be widely used in the refining of bio-gasoline.

An anti-smudge body having a surface that, when fingerprints adhere to the surface, allows the fingerprint patterns to spread spontaneously to thereby cause them to become less noticeable has the surface and a plurality of protrusions provided thereto. The protrusions contain at least one of a first compound having an ester linkage in a portion other than terminal ends and a second compound having a cyclic hydrocarbon group.

An anti-glare film comprises a substrate film comprising a cycloolefinic polymer, an anti-glare layer, and an adhesive layer formed between the substrate film and the anti-glare layer. In the anti-glare film, the adhesive layer is (A-1) a cured layer of (A-2) a curable composition containing at least (A-3) a curable component selected from the group consisting of a mono- or di(meth)acrylate having an alicyclic hydrocarbon ring and a mono- or di(meth)acrylate having a crosslinked cyclic hydrocarbon ring; the anti-glare layer is (B-1) a cured layer of (B-2) a curable resin composition and has a phase separation structure and an uneven surface structure, and the curable resin composition (B-2) comprises a plurality of components being capable of phase separation and containing at least (B-3) a curable component.